| Style | Citing Format |
|---|---|
| MLA | Mirasheh M, et al.. "Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes." Diseases, vol. 14, no. 8, 2026, pp. -. |
| APA | Mirasheh M, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee D Y (2026). Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes. Diseases, 14(8), -. |
| Chicago | Mirasheh M, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee D Y. "Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes." Diseases 14, no. 8 (2026): -. |
| Harvard | Mirasheh M et al. (2026) 'Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes', Diseases, 14(8), pp. -. |
| Vancouver | Mirasheh M, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee D Y. Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes. Diseases. 2026;14(8):-. |
| BibTex | @article{ author = {Mirasheh M and Shahabinia Z and Mazidimoradi A and Allahqoli L and Salehiniya H and Lee D Y}, title = {Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes}, journal = {Diseases}, volume = {14}, number = {8}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Mirasheh M AU - Shahabinia Z AU - Mazidimoradi A AU - Allahqoli L AU - Salehiniya H AU - Lee D Y TI - Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes JO - Diseases VL - 14 IS - 8 SP - EP - PY - 2026 ER - |